CPI-0209 + Carboplatin for Ovarian Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug, CPI-0209, combined with chemotherapy in patients with recurrent ovarian cancer. The goal is to see if CPI-0209 can make chemotherapy work better and prevent the cancer from returning by blocking resistance and spread.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot take warfarin or certain herbal supplements. Foods like grapefruit that affect drug metabolism must be avoided starting 7 days before the trial.
What data supports the effectiveness of the drug combination CPI-0209 and Carboplatin for ovarian cancer?
Carboplatin has been shown to be effective in treating ovarian cancer, with response rates similar to cisplatin but with fewer side effects. It is often used in combination with other drugs for better outcomes, and studies have shown it to be effective in both first-line and recurrent ovarian cancer treatments.12345
Is the combination of CPI-0209 and Carboplatin safe for treating ovarian cancer?
Carboplatin, used in various studies for different cancers, generally shows mild side effects like nausea and more serious blood-related issues like low platelet counts (thrombocytopenia). It has been used safely in combination with other drugs, but specific safety data for CPI-0209 combined with Carboplatin is not available in the provided research.678910
How is the drug CPI-0209 + Carboplatin unique for treating ovarian cancer?
The combination of CPI-0209 and Carboplatin is unique because it pairs a novel drug, CPI-0209, with Carboplatin, a well-established chemotherapy agent, potentially enhancing the treatment's effectiveness against ovarian cancer. While Carboplatin is known for its activity in ovarian cancer, CPI-0209 may offer a new mechanism of action that could improve outcomes, especially in cases where traditional treatments have been less effective.310111213
Research Team
Lan G Coffman, MD
Principal Investigator
UPMC Magee Women's Hospital
Eligibility Criteria
This trial is for women with ovarian cancer that has returned more than 6 months after platinum-based chemotherapy. They must be able to take oral medication, have a life expectancy of at least 3 months, and agree to use effective contraception. Exclusions include certain medical conditions, recent treatments or surgeries, and those not recovered from previous therapy side effects.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CPI-0209 in combination with Carboplatin chemotherapy
Maintenance
Participants continue with CPI-0209 maintenance therapy to prolong disease-free interval
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Carboplatin (Alkylating agents)
- CPI-0209 (Epigenetic Modulator)
Carboplatin is already approved in Canada for the following indications:
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Lan Coffman
Lead Sponsor
MorphoSys AG
Industry Sponsor
National Cancer Institute (NCI)
Collaborator